Duo Oncology Completes Favorable PreIND Meeting

May 17, 2022, 4:00:00 AM

DUO ONCOLOGY ANNOUNCES SUCCESSFUL COMPLETION OF A PRE-IND MEETING WITH THE FDA. Favorable Written Option Confirms Clear Roadmap for DUO-207 Develop as First-Line Therapy for Pancreatic Cancer and Other Solid Malignancies.

Duo Oncology Completes Favorable PreIND Meeting